乙型肝炎病毒DNA整合及抗病毒治疗对其作用的研究进展  

Research progress on the effect of hepatitis B virus DNA integration on antiviral therapy

作　　者：赵景[1] 陈新月[1] 郑素军[1] Zhao Jing;Chen Xinyue;Zheng Sujun(First Department of Liver Disease Center,Beijing Youan Hospital,Capital Medical University,Beijing 100069,China)

机构地区：[1]首都医科大学附属北京佑安医院肝病中心一科,北京100069

出　　处：《中华肝脏病杂志》2024年第4期375-379,共5页Chinese Journal of Hepatology

基　　金：北京自然科学基金(7222093);北京市卫生健康委员会高层次公共卫生技术人才建设项目(学科带头人-02-14);首都临床诊疗技术研究及转化应用(Z211100002921059)。

摘　　要：乙型肝炎病毒(HBV)DNA整合发生于HBV复制的逆转录过程中,在HBV感染的早期即已发生并伴随整个病程。整合HBVDNA不利于临床治愈目标的达成,亦增加了发生肝癌的风险。理论上,核苷(酸)类似物可以减少新双链线性DNA合成,但对已存在HBV整合的肝细胞无清除功能,故血清HBVDNA阴转的患者仍存在发展为肝癌的风险;而干扰素作为一种免疫调节药物,不仅可以抑制病毒复制,还可以抑制甚至清除既存的携带整合HBVDNA片段的克隆性扩增肝细胞。然而,目前核苷(酸)类似物与干扰素治疗对HBVDNA整合影响的研究尚少,函需开展大样本的的临床研究来进一步明确。Hepatitis B virus(HBV)DNA integration occurs during the reverse transcription process of HBV replication,which develops in the early stages of HBV infection and accompanies the entire disease course.The integration of HBV DNA is detrimental to the attainment of clinical cure goals and also raises the risk of developing liver cancer.Theoretically,nucleos(t)ide analogs can reduce the synthesis of new double-stranded linear DNA,but there is no clearance function for hepatocytes that have already integrated HBV.Therefore,patients with serum HBV DNA-negative conversions still have the risk of developing liver cancer.As an immunomodulatory drug,interferon can not only inhibit viral replication but also inhibit or even eliminate existing clonally amplified hepatocytes carrying integrated HBV DNA fragments.However,there are currently few studies on the effects of nucleos(t)ide analogues and interferon therapy on HBV DNA integration.Thus,large-scale clinical studies are urgently needed for further clarification.

关 键 词：乙型肝炎病毒 DNA整合 临床治愈 肝细胞癌 核苷(酸)类似物 干扰素 

分 类 号：R512.62[医药卫生—内科学]